Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02222389 · ClinicalTrials.gov registry record · NA

Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse

A NA study, sponsored by Washington State University.

Completed
Registry status
NA
Development phase
120
Enrollment target

NCT02222389: Completed NA study, sponsored by Washington State University.

NCT02222389 is a NA study that has completed, run by Washington State University. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02222389, a NA study, has completed, sponsored by Washington State University.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

Contingency management (CM) is a type of treatment used in the substance abuse field. Patients' behaviors are rewarded for adherence to a treatment plan. As an approach to treatment, contingency management emerged from the behavior therapy traditions in mental health. By most evaluations, contingency management procedures produce one of the largest effect sizes out of all mental health and educational interventions. The purpose of this study is to perform a randomized, controlled trial to evaluate the ability of a culturally-tailored contingency management (CM) intervention to increase alcohol and drug abstinence among American Indian (AI) tribal members from two rural reservations in the Northwest.

Primary Outcome

At every study visit, urine samples will be collected and analyzed for ethyl glucuronide and drugs. This helps assess Contingency Management as a treatment for alcohol and/or drug dependence.

Interventions

  • BEHAVIORAL CM for Alcohol
  • BEHAVIORAL CM for drugs
  • BEHAVIORAL CM for both substances
  • BEHAVIORAL Non-Contingent group

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2015-06-01
Est. Completion 2018-09-10
Phase NA
Washington State University

64 total trials

What the finished NCT02222389 record still lists

NCT02222389 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 4 interventions - of which CM for Alcohol is the first listed.

NCT02222389 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02222389 about?

NCT02222389 is a clinical study titled "Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse". Contingency management (CM) is a type of treatment used in the substance abuse field. Patients' behaviors are rewarded for adherence to a treatment plan. As an approach to treatment, contingency management emerged from the behavior therapy traditions in mental health. By most evaluations, contingenc...

What is the current status of trial NCT02222389?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2015-06-01. Estimated completion is 2018-09-10.

What interventions are being tested in trial NCT02222389?

The interventions under investigation include: CM for Alcohol (BEHAVIORAL), CM for drugs (BEHAVIORAL), CM for both substances (BEHAVIORAL), Non-Contingent group (BEHAVIORAL).

Who is sponsoring clinical trial NCT02222389?

This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02222389's enrollment target sits among peer trials

120 762nd of 2000 higher than 1,198 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02222389, the US trial registry maintained by the National Library of Medicine. NCT02222389 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.